Header Logo

Connection

MALCOLM BRENNER to Graft vs Host Disease

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Graft vs Host Disease.
MALCOLM BRENNER
Connection Strength
2.799
Graft vs Host Disease
  1. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
    View in: PubMed
    Score: 0.378
  2. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.362
  3. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.284
  4. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
    View in: PubMed
    Score: 0.209
  5. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.156
  6. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
    View in: PubMed
    Score: 0.135
  7. Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019.
    View in: PubMed
    Score: 0.098
  8. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
    View in: PubMed
    Score: 0.094
  9. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
    View in: PubMed
    Score: 0.089
  10. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7.
    View in: PubMed
    Score: 0.084
  11. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.083
  12. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
    View in: PubMed
    Score: 0.083
  13. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.078
  14. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6.
    View in: PubMed
    Score: 0.077
  15. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
    View in: PubMed
    Score: 0.065
  16. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24.
    View in: PubMed
    Score: 0.054
  17. The use of monoclonal antibodies in graft versus host disease prevention. Haematologia (Budap). 1986; 19(3):167-76.
    View in: PubMed
    Score: 0.047
  18. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
    View in: PubMed
    Score: 0.039
  19. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.034
  20. Placental blood transplant: who will benefit? Nat Med. 1996 Sep; 2(9):969-70.
    View in: PubMed
    Score: 0.025
  21. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.023
  22. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.021
  23. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.021
  24. Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
    View in: PubMed
    Score: 0.020
  25. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
    View in: PubMed
    Score: 0.018
  26. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49.
    View in: PubMed
    Score: 0.017
  27. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
    View in: PubMed
    Score: 0.017
  28. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
    View in: PubMed
    Score: 0.015
  29. Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
    View in: PubMed
    Score: 0.015
  30. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
    View in: PubMed
    Score: 0.015
  31. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
    View in: PubMed
    Score: 0.014
  32. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.014
  33. [Therapeutic advances in bone marrow transplantation]. Clin Ter. 1987 Sep 15; 122(5):321-32.
    View in: PubMed
    Score: 0.013
  34. Bone marrow transplantation in acute or chronic leukaemia. Acta Haematol. 1987; 78 Suppl 1:194-7.
    View in: PubMed
    Score: 0.013
  35. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
    View in: PubMed
    Score: 0.013
  36. T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 1986 Dec; 103(2):476-80.
    View in: PubMed
    Score: 0.013
  37. T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol. 1986 Mar; 63(3):577-86.
    View in: PubMed
    Score: 0.012
  38. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
    View in: PubMed
    Score: 0.012
  39. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
    View in: PubMed
    Score: 0.012
  40. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71.
    View in: PubMed
    Score: 0.007
  41. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
    View in: PubMed
    Score: 0.006
  42. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.005
  43. Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor pool. Acta Oncol. 1988; 27(5):567-70.
    View in: PubMed
    Score: 0.003
  44. Standardization of T-cell depletion in HLA matched bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):69-75.
    View in: PubMed
    Score: 0.003
  45. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986 Feb 15; 1(8477):339-43.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.